AstraZeneca PLC is 2.5x more valuable than Bristol-Myers Squibb Company by market capitalization ($286.27 B vs $113.54 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | BMY | AZN |
|---|---|---|
| Market cap | $113.54 B | $286.27 B |
| US-listed rank | #132 | #45 |
| Revenue (latest FY) | $48.19B | - |
| Net income (latest FY) | $7.05B | - |
| Net margin | 14.6% | - |
| P/E (trailing FY) | 16.1 | - |
| SEC filings | 1,000 | 1,004 |
AstraZeneca PLC is 2.5x more valuable than Bristol-Myers Squibb Company by market capitalization ($286.27 B vs $113.54 B).
Full pages: Bristol-Myers Squibb Company and AstraZeneca PLC, or browse the full rankings.